Defining intermediate-risk non-muscle-invasive bladder cancer

被引：0
|
作者：
S. Bruce Malkowicz
机构：
[1] Perelman School of Medicine,Division of Urology, Department of Surgery
[2] University of Pennsylvania,undefined
来源：
Nature Reviews Urology | 2014年 / 11卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The pathology of intermediate-risk non-muscle-invasive bladder cancer is less well-defined than both high-risk and low-risk presentations of this disease. Recently reported guidelines seek to aid clinicians in classification of intermediate-risk patients, and also provide treatment recommendations for this subgroup.
引用
收藏
页码：430 / 432
页数：2
相关论文
共 50 条
  • [1] BLADDER CANCER Defining intermediate-risk non-muscle-invasive bladder cancer
    Malkowicz, S. Bruce
    NATURE REVIEWS UROLOGY, 2014, 11 (08) : 430 - 432
  • [2] Adjuvant therapy in intermediate-risk non-muscle-invasive bladder cancer
    Laukhtina, E.
    Moschini, M.
    Soria, F.
    Pradere, B.
    Yanagisawa, T.
    Kawada, T.
    Quhal, F.
    Von, Deimling M.
    Rajwa, P.
    Majdoub, M.
    Enikeev, D.
    Karakiewicz, P., I
    Robert, R. S.
    Babjuk, M.
    Shariat, S. F.
    EUROPEAN UROLOGY, 2023, 83
  • [3] Treatment of intermediate-risk non-muscle-invasive bladder cancer (NMIBC)
    Hendricksen, Kees
    Witjes, J. Alfred
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (14) : 800 - 808
  • [4] Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer
    Laukhtina, Ekaterina
    Gontero, Paolo
    Babjuk, Marko
    Moschini, Marco
    Teoh, Jeremy Yuen-Chun
    Roupret, Morgan
    Trinh, Quoc-Dien
    Chlosta, Piotr
    Nyirady, Peter
    Abufaraj, Mohammad
    Soria, Francesco
    Klemm, Jakob
    Bekku, Kensuke
    Matsukawa, Akihiro
    Shariat, Shahrokh F.
    BJU INTERNATIONAL, 2024,
  • [5] Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non-muscle-invasive Bladder Cancer
    Fukushima, Hiroshi
    Moriyama, Shingo
    Waseda, Yuma
    Fukuda, Shohei
    Uehara, Sho
    Tanaka, Hajime
    Kijima, Toshiki
    Yoshida, Soichiro
    Yokoyama, Minato
    Ishioka, Junichiro
    Matsuoka, Yoh
    Saito, Kazutaka
    Fujii, Yasuhisa
    EUROPEAN UROLOGY FOCUS, 2021, 7 (02): : 366 - 372
  • [6] Intermediate-risk Non-muscle-invasive Bladder Cancer: Time To Tidy Up the Mess?
    Soria, Francesco
    Gontero, Paolo
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (05): : 517 - 518
  • [7] Characterizing intermediate-risk non-muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy
    Matsumoto, Kazuhiro
    Kikuchi, Eiji
    Yanai, Yoshinori
    Hayakawa, Nozomi
    Ito, Yujiro
    Maeda, Takahiro
    Nagata, Hirohiko
    Miyajima, Akira
    Oya, Mototsugu
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (05) : 208 - 214
  • [8] Cancer Patients: Implications for Adjuvant Therapies Stratification of Intermediate-risk Non-muscle-invasive Bladder
    Soria, Francesco
    D'Andrea, David
    Abufaraj, Mohammad
    Moschini, Marco
    Giordano, Andrea
    Gust, Kilian M.
    Karakiewicz, Pierre I.
    Babjuk, Marek
    Gontero, Paolo
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY FOCUS, 2021, 7 (03): : 566 - 573
  • [9] Management of Low-risk and Intermediate-risk Non-Muscle-invasive Bladder Carcinoma
    Weijers, Yme
    Arentsen, Harm C.
    Arends, Tom J. H.
    Witjes, J. Alfred
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 29 (02) : 219 - +
  • [10] The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
    Chen, Jian-Xin
    Huang, Wen-Ting
    Zhang, Qing-Yun
    Deng, Cheng-En
    Wei, Jue-ling
    Xie, Yuan-Liang
    Lin, Rui
    Feng, Guan-Zheng
    Yang, Guang-Lin
    Long, Jun
    Lu, Hao-Yuan
    Mo, Zeng-nan
    BMC CANCER, 2023, 23 (01)
12345